Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Flexion acquires GQ-203 from GeneQuine
March 2018
SHARING OPTIONS:

BURLINGTON, Mass.—A definitive agreement has been signed between Flexion Therapeutics Inc. and GeneQuine Biotherapeutics GmbH under which the former will acquire global rights to GQ-203, a preclinical non-opioid, intra-articular therapeutic under development for symptomatic pain relief and disease modification in patients with osteoarthritis of the knee. Under the agreement, Flexion gains an exclusive license to the intellectual property rights for human use of the compound from Baylor College of Medicine. Flexion will pay $2 million to GeneQuine up front, with the potential for additional milestone payments of up to $8.7 million through Phase 2 proof of concept. Should that be reached, GeneQuine could receive up to $54 million in development and global regulatory approval payments, with Baylor receiving a low single-digit royalty on net sales of GQ-203.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.